News Search Results
Apr 30, 2026, 02:30 ET Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases
Formosa Pharmaceuticals, Inc.Formosa Pharmaceuticals is a biopharmaceutical company focused on areas of unmet medical need, primarily in ophthalmology and oncology. The company's proprietary APNT® technology provides a streamlined pathway for the formulation of poorly soluble
More news about: Formosa Pharmaceuticals Inc.,
Apr 29, 2026, 10:05 ET Vascular Endothelial Growth Factor Inhibitors Market to Reach USD 33.5 Billion by 2036, Driven by Rising Cancer Burden, Biosimilar Expansion, and Shift Toward Subcutaneous Therapies
Growth is further supported by expanding use in ophthalmology, increasing biosimilar penetration, and continuous innovation in targeted therapies and drug delivery systems.Quick Stats: Vascular Endothelial
More news about: Future Market Insights
Apr 28, 2026, 15:51 ET Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Limited
Apr 28, 2026, 15:40 ET Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Limited
Apr 28, 2026, 09:30 ET New Verana Health AI Agent Boosts Efficiency and Compliance in MIPS Submissions
and improving performance, and is now available in the Quality Measures Dashboard application for qualifying members of the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight).
More news about: Verana Health
Apr 28, 2026, 08:11 ET Prevent Blindness Debuts "Best Eyes for Life" National Multimedia Campaign as Survey Reveals Concerning Misconceptions on Eye Health
significant vision loss later in life," said R.V. Paul Chan, MD, MSc, FACS, member, Prevent Blindness Board of Directors and professor and chair of ophthalmology at the University of Illinois College of Medicine, director of the Pediatric Retina and Retinopathy of Prematurity Service at UI Health. "It is
More news about: Prevent Blindness
Apr 28, 2026, 08:00 ET Trinity Capital Inc. Provides $30 Million in Growth Capital to Iantrek to Accelerate Commercial Expansion and Advance Product Pipeline
believe Iantrek's innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We are pleased to support their team as they enter this next phase
More news about: Trinity Capital Inc.
Apr 28, 2026, 06:30 ET Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
development portfolio with a focus on genetically-defined neurological diseases. Earlier, he served as the Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development at Sanofi Genzyme, where he oversaw global regulatory approvals of the MS drugs LEMTRADA® (alemtuzumab)
More news about: Immunic, Inc.
Apr 27, 2026, 11:30 ET Avirmax Biopharma Inc. Proudly Presents at the 2026 ARVO Annual Meeting in Denver, Colorado
two scientific presentations at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, Colorado May 3 - 7, 2026. ARVO is the largest international society dedicated to ophthalmology and related visual sciences.
More news about: Avirmax
Apr 27, 2026, 11:00 ET SightMD's Dr. Eric Rosenberg Becomes First Surgeon in the World to Perform Cataract Surgery Using Apple Vision Pro Mixed Reality
www.sightmd.com or call 855.295.4144.SightMD New York is actively seeking ophthalmology professionals who are interested in joining its outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact the Chief Medical Officer,
More news about: SightMD
Apr 27, 2026, 10:15 ET Prevent Blindness Declares May as Third Annual Inherited Retinal Disease and Genetic Testing Month, Offering Resources to Public and Healthcare Allies, to Help Save Sight
Inherited Retinal Disorders and Genetic Testing," with Alina V. Dumitrescu, MD, Clinical Associate Professor of Ophthalmology and Visual Sciences, Pediatric Ophthalmology and Strabismus, Inherited Eye Disease at the University of Iowa Hospitals and Clinics.RP videos featuring
More news about: Prevent Blindness
Apr 27, 2026, 08:00 ET Stealth BioTherapeutics to Present Clinical Data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting
ascending dose (SAD) and multiple ascending dose (MAD) parts of the trial will be presented at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held on May 3-7 in Denver, Colo.
More news about: Stealth BioTherapeutics Inc.
Apr 27, 2026, 08:00 ET Avista Therapeutics Announces Presentations at Upcoming Medical Meetings
28-30 in Rome, Italy, in addition to the acceptance of multiple abstracts for poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) being held May 3-7 in Denver, Colorado, and the American Society of Gene & Cell Therapy (ASGCT) being held May 11-15 in Boston, Massachusetts.
More news about: Avista Therapeutics
Apr 23, 2026, 13:29 ET Prevent Blindness Kicks Off its 2026 Focus on Eye Health Webinar Series "Powering Partnerships to Advance Eye Health" in May
MPA, Senior Director of Government Affairs, Prevent BlindnessScott Haber, MPA, Director, Public Health Advocacy at American Academy of OphthalmologyM. Araba Otoo OD, MPH, FAAO, Chair, American Public Health Association Vision Care Section, CEO, Cherish Eyesight & Vision Inc., and
More news about: Prevent Blindness
Apr 23, 2026, 07:00 ET Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2026 Annual Meetings
ARVO, The Association for Research in Vision and OphthalmologySunday, May 3rd to Thursday, May 7th, 2026Colorado Convention Center, Denver, COPresenter:
More news about: Nanoscope Therapeutics
Apr 23, 2026, 03:00 ET MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can be found at
More news about: Specialised Therapeutics
Apr 22, 2026, 11:07 ET Brain Support Cells Form Previously Unknown Network
Alzheimer's and Parkinson's disease," said study co-senior author Shane A. Liddelow, PhD. Dr. Liddelow is an associate professor in the neuroscience and ophthalmology departments at NYU Grossman School of Medicine.Another key finding was that astrocyte networks are dynamic. When the team trimmed whiskers
More news about: NYU Grossman School of Medicine and NYU Langone Health
Apr 21, 2026, 20:00 ET Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its first-in-class IBI363 (PD-1/IL-2α-biased bispecific fusion protein) *
More news about: Innovent Biologics
Apr 21, 2026, 08:00 ET Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Apr 20, 2026, 06:45 ET U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Apr 20, 2026, 02:30 ET New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can be found at
More news about: Specialised Therapeutics
Apr 18, 2026, 19:01 ET Penn Medicine, Children's Hospital of Philadelphia team awarded Breakthrough Prize for developing gene therapy for inherited blindness
Albert Maguire, MD, both emeritus professors of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania, and
More news about: Children's Hospital of Philadelphia
Apr 17, 2026, 10:00 ET SightMD Wins "Best of Brooklyn" in Ophthalmologist / Optometrist and LASIK Surgery Practice Categories
www.SightMD.com or call (718) 577-4722.SightMD New York is actively seeking ophthalmology professionals who are interested in joining its outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact the Chief Medical Officer,
More news about: SightMD
Apr 17, 2026, 08:00 ET Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Executive Vice President, Global Head of Specialty Medicine. During his tenure, he provided leadership across multiple therapeutic areas, including ophthalmology, neurology, hematology, and cardiology, and oversaw the global launch of EYLEA®. Mr. Dable currently serves as an advisor at RA Capital Management,
More news about: Tyra Biosciences
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics
More news about: Piramal Pharma Solutions